328 related articles for article (PubMed ID: 33677596)
1. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies.
He P; Hu JP; Tian XJ; He LJ; Sun SR; Huang C
Rheumatology (Oxford); 2021 Mar; 60(3):1067-1079. PubMed ID: 33677596
[TBL] [Abstract][Full Text] [Related]
2. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
5. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
7. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
Pagnoux C; Hogan SL; Chin H; Jennette JC; Falk RJ; Guillevin L; Nachman PH
Arthritis Rheum; 2008 Sep; 58(9):2908-18. PubMed ID: 18759282
[TBL] [Abstract][Full Text] [Related]
8. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
10. [ANCA-vasculitis with renal impairment treated by intravenous versus oral cyclophosphamide: Multicentric analysis of relapse free survival (VaReCyS)].
Gouin JB; Dhalluin T; Perrichot R; Vigneau C; Michel A
Nephrol Ther; 2020 Jul; 16(4):201-210. PubMed ID: 32653427
[TBL] [Abstract][Full Text] [Related]
11. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
12. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis.
Berti A; Alsawas M; Jawaid T; Prokop LJ; Lee JM; Jeong GH; Quintana LF; Moiseev S; Vaglio A; Tesar V; Geetha D; Shin JIL; Kronbichler A
Nephrol Dial Transplant; 2022 Oct; 37(11):2190-2200. PubMed ID: 34910216
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
17. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
18. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
19. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]